Procore signs multi-year strategic collaboration agreement with AWS
Investing.com -- Bausch + Lomb Corporation (NYSE/TSX:BLCO) on Wednesday reported second-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of $0.07 beating estimates by $0.01 and revenue of $1.29 billion surpassing the consensus of $1.26 billion.
The company’s shares edged up 0.07% following the announcement.
The global eye health company posted a 5% increase in total revenue compared to the same quarter last year, or 3% growth on a constant currency basis.
This growth came despite challenges from the voluntary recall of enVista intraocular lenses.
The company reported a GAAP net loss of $62 million, or -$0.18 per share, an improvement from the -$0.43 per share loss in the second quarter of 2024.
Vision Care, the company’s largest segment, drove performance with revenue of $753 million, up 8% year-over-year, or 6% on a constant currency basis.
The growth was fueled by strong sales in the dry eye portfolio and contact lens business.
"Our continued growth speaks to the breadth and depth of our portfolio and is driven by a mix of hero products and a steady stream of new introductions around the world," said Brent Saunders, chairman and CEO of Bausch + Lomb.
Following the solid quarterly performance, the company raised its full-year 2025 guidance, now projecting revenue between $5.05 billion and $5.15 billion, above the analyst consensus of $5.03 billion.
This represents approximately 5-7% growth on a constant currency basis.
The company also increased its adjusted EBITDA guidance excluding acquired IPR&D to between $860 million and $910 million.
The company highlighted several achievements, including resuming full production of all enVista platform IOLs following their return to market and reaching approximately $1 billion in trailing 12-month revenue across its dry eye portfolio.
Cash flow from operations improved to $35 million for the quarter, up from $15 million in the same period last year, primarily due to improvements in working capital.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.